Paiola, M., Portnoy, D. M., Hao, L. Y., Bukhari, S., Winchester, R. J., Henick, B. S., Mor, A., & Gartshteyn, Y. (2025). Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells. Journal for ImmunoTherapy of Cancer, 13(3), e010758. https://doi.org/10.1136/jitc-2024-010758

Haile, H., Upadhyayula, P. S., Karlovich, E., Sisti, M. B., Gill, B. J. A., & Donovan, L. E. (2025). Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report. Acta Neuropathologica Communications, 13(1). https://doi.org/10.1186/s40478-024-01894-w

In, G. K., Ribeiro, J. R., Yin, J., Xiu, J., Bustos, M. A., Ito, F., Chow, F., Zada, G., Hwang, L., Salama, A. K. S., Park, S. J., Moser, J. C., Darabi, S., Domingo-Musibay, E., Ascierto, M. L., Margolin, K., Lutzky, J., Gibney, G. T., Atkins, M. B., … VanderWalde, A. M. (2023). Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases. Npj Precision Oncology, 7(1). https://doi.org/10.1038/s41698-023-00471-z

Fu, J., Li, S., Liu, G., MA, H., Marcireau, C., Mapara, M., & Lentzsch, S. (2023). Synergistic Anti-Tumor Effects in RAS Mut Multiple Myeloma By Targeting MAP4K2 and RAS Pathways. Blood, 142(Supplement 1), 6618–6618. https://doi.org/10.1182/blood-2023-190740

Patel, S., Mckean, M., Piperno-Neumann, S., Shoushtari, A. N., Hernandez-Aya, L., Orloff, M., Khan, S., Montazeri, K., Kapiteijn, E., Buchbinder, E., Agresta, S., Reilly, S., Patriquin, C. M., Hickman, D., Corrigan, D., Granlund, L., Hentemann, M., Piel, J., Martin, P., & Mehmi, I. (2023). 1128P A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma. Annals of Oncology, 34, S677–S678. https://doi.org/10.1016/j.annonc.2023.09.2262

Bauer, S., Larkin, J., Hodi, F. S., Stephen, F., Kapiteijn, E. H. W., Schwartz, G. K., Calvo, E., Yerramilli-Rao, P., Piperno-Neumann, S., & Carvajal, R. D. (2023). A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.975642

Kim, S., Carvajal, R., Kim, M., & Yang, H. W. (2023). Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma. Cell Reports, 42(6), 112570. https://doi.org/10.1016/j.celrep.2023.112570

Patterson, V., Ullah, F., Bryant, L., Li, D., Griffin, J. N., Sidhu, A., Saliganan, S., Blaile, M., Saenz, M. S., Smith, R., Ellingwood, S., Grange, D. K., Hu, X., Mireguli, M., Luo, Y., Shen, Y., Mulhern, M., Zackai, E., Ritter, A., … Bhoj, E. (2023). Abrogation of MAP4K4 protein function causes congenital anomalies in humans and zebrafish. Science Advances, 9(17). https://doi.org/10.1126/sciadv.ade0631

Ozturk, D. G., Özkan, H., Akcan, U., & Korkmaz, G. (2023). 23P Synthetic lethality by targeting RHEB in ARID1A-mutated luminal breast cancer. ESMO Open, 8(1), 100989. https://doi.org/10.1016/j.esmoop.2023.100989

Maniar, R., Gallitano, S. M., Husain, S., Moazami, G., Weiss, M. J., & Shu, C. A. (2023). Unusual Adverse Events in a Patient With BRAF-Mutated Non–Small Cell Lung Cancer Treated With BRAF/MEK Inhibition. Journal of the National Comprehensive Cancer Network, 21(3), 232–234. https://doi.org/10.6004/jnccn.2022.7084

Li, S., Fu, J., Yang, J., Ma, H., Mapara, M. Y., Marcireau, C., & Lentzsch, S. (2022). MAP4K2 Inhibition Reinforces the Iberdomide Sensitivity in MM Cells By Inducing IKZF1 Degradation through a CRBN Independent Mechanism. Blood, 140(Supplement 1), 4224–4225. https://doi.org/10.1182/blood-2022-168314